Damora Therapeutics (DMRA) Cash from Investing Activities (2021 - 2024)

Damora Therapeutics has reported Cash from Investing Activities for 4 years, with the latest figure at $6.0 million in Q2 2024.

• For the quarter ending Q2 2024, Cash from Investing Activities rose 94.11% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2024 stood at $11.6 million (down 47.83% YoY), and the FY2025 full-year result was -$17.4 million, down 249.13% from the prior year.
• Cash from Investing Activities for Q2 2024 stood at $6.0 million, up from $5.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $14.4 million in Q4 2021, with the low at -$74.6 million in Q1 2021.
• Historically, Cash from Investing Activities has averaged -$120285.7 across 4 years, with a median of $5.8 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 101.0% — and 2023, when it jumped 6160.78%.
• Damora Therapeutics' Cash from Investing Activities stood at $14.4 million in 2021, then dropped by 0.57% to $14.3 million in 2022, then tumbled by 33.15% to $9.6 million in 2023, then slumped by 37.37% to $6.0 million in 2024.
• The last three Cash from Investing Activities figures came in at $6.0 million (Q2 2024), $5.6 million (Q1 2024), and $9.6 million (Q4 2023), per Business Quant data.